Limits...
Osteosarcoma in Korean children and adolescents.

Lee JA - Korean J Pediatr (2015)

Bottom Line: Osteosarcoma is the most frequent primary bone tumor.The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients.This article provides an overview of current therapies for osteosarcoma in Korea.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.

ABSTRACT
Osteosarcoma is the most frequent primary bone tumor. Advances in combination chemotherapy and surgical technique have greatly improved the survival of patients with osteosarcoma. In Korea, improvements in osteosarcoma treatment have been made over the past two decades. The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients. This article provides an overview of current therapies for osteosarcoma in Korea.

No MeSH data available.


Related in: MedlinePlus

The Korean Society of Pediatric Hematology and Oncology retrospective study: administered preoperative and postoperative chemotherapy regimens. CA, cisplatin+doxorubicin; MCA, high-dose methotrexate (HD MTX)+cisplatin+doxorubicin; MIA, HD MTX+ifosfamide+doxorubicin; MCAI, HD MTX+cisplatin+doxorubicin+ifo sfamide.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4414626&req=5

Figure 1: The Korean Society of Pediatric Hematology and Oncology retrospective study: administered preoperative and postoperative chemotherapy regimens. CA, cisplatin+doxorubicin; MCA, high-dose methotrexate (HD MTX)+cisplatin+doxorubicin; MIA, HD MTX+ifosfamide+doxorubicin; MCAI, HD MTX+cisplatin+doxorubicin+ifo sfamide.

Mentions: Treatments were heterogeneous, depending on treatment era or institutional policy. The majority of patients (252 cases, 78.0%) were treated in a standard fashion with preoperative chemotherapy followed by surgery and postoperative chemotherapy. Of the 280 patients that underwent surgery, limb salvage was performed in 253 cases (90.4%). High-dose methotrexate (HD MTX), cisplatin, doxorubicin, and ifosfamide were the core components of combination chemotherapy. Chemotherapy regimens differed between institutions (Fig. 1). Postoperative chemotherapy was modified in 122 cases (37.8%) due to poor histological response (viable tumor cell>10%) to preoperative chemotherapy.


Osteosarcoma in Korean children and adolescents.

Lee JA - Korean J Pediatr (2015)

The Korean Society of Pediatric Hematology and Oncology retrospective study: administered preoperative and postoperative chemotherapy regimens. CA, cisplatin+doxorubicin; MCA, high-dose methotrexate (HD MTX)+cisplatin+doxorubicin; MIA, HD MTX+ifosfamide+doxorubicin; MCAI, HD MTX+cisplatin+doxorubicin+ifo sfamide.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4414626&req=5

Figure 1: The Korean Society of Pediatric Hematology and Oncology retrospective study: administered preoperative and postoperative chemotherapy regimens. CA, cisplatin+doxorubicin; MCA, high-dose methotrexate (HD MTX)+cisplatin+doxorubicin; MIA, HD MTX+ifosfamide+doxorubicin; MCAI, HD MTX+cisplatin+doxorubicin+ifo sfamide.
Mentions: Treatments were heterogeneous, depending on treatment era or institutional policy. The majority of patients (252 cases, 78.0%) were treated in a standard fashion with preoperative chemotherapy followed by surgery and postoperative chemotherapy. Of the 280 patients that underwent surgery, limb salvage was performed in 253 cases (90.4%). High-dose methotrexate (HD MTX), cisplatin, doxorubicin, and ifosfamide were the core components of combination chemotherapy. Chemotherapy regimens differed between institutions (Fig. 1). Postoperative chemotherapy was modified in 122 cases (37.8%) due to poor histological response (viable tumor cell>10%) to preoperative chemotherapy.

Bottom Line: Osteosarcoma is the most frequent primary bone tumor.The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients.This article provides an overview of current therapies for osteosarcoma in Korea.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.

ABSTRACT
Osteosarcoma is the most frequent primary bone tumor. Advances in combination chemotherapy and surgical technique have greatly improved the survival of patients with osteosarcoma. In Korea, improvements in osteosarcoma treatment have been made over the past two decades. The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients. This article provides an overview of current therapies for osteosarcoma in Korea.

No MeSH data available.


Related in: MedlinePlus